Fonar (FONR) Competitors $15.41 -0.21 (-1.34%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$15.60 +0.19 (+1.23%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FONR vs. TMCI, NPCE, OM, CLPT, NNOX, ZIMV, SNWV, CATX, NYXH, and DRTSShould you be buying Fonar stock or one of its competitors? The main competitors of Fonar include Treace Medical Concepts (TMCI), NeuroPace (NPCE), Outset Medical (OM), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), ZimVie (ZIMV), Sanuwave Health (SNWV), Perspective Therapeutics (CATX), Nyxoah (NYXH), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry. Fonar vs. Its Competitors Treace Medical Concepts NeuroPace Outset Medical ClearPoint Neuro Nano-X Imaging ZimVie Sanuwave Health Perspective Therapeutics Nyxoah Alpha Tau Medical Treace Medical Concepts (NASDAQ:TMCI) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Does the media refer more to TMCI or FONR? In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 1 articles in the media. Fonar's average media sentiment score of 1.87 beat Treace Medical Concepts' score of 1.86 indicating that Fonar is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fonar 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is TMCI or FONR more profitable? Fonar has a net margin of 8.19% compared to Treace Medical Concepts' net margin of -25.14%. Fonar's return on equity of 5.31% beat Treace Medical Concepts' return on equity.Company Net Margins Return on Equity Return on Assets Treace Medical Concepts-25.14% -48.69% -24.59% Fonar 8.19%5.31%3.97% Which has higher earnings and valuation, TMCI or FONR? Fonar has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTreace Medical Concepts$209.36M1.83-$55.74M-$0.85-7.16Fonar$102.88M0.93$10.57M$1.2512.33 Do analysts prefer TMCI or FONR? Treace Medical Concepts currently has a consensus price target of $10.16, indicating a potential upside of 66.78%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, analysts plainly believe Treace Medical Concepts is more favorable than Fonar.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Treace Medical Concepts 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29Fonar 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in TMCI or FONR? 84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 27.7% of Treace Medical Concepts shares are held by company insiders. Comparatively, 1.6% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, TMCI or FONR? Treace Medical Concepts has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Fonar has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. SummaryFonar beats Treace Medical Concepts on 8 of the 15 factors compared between the two stocks. Get Fonar News Delivered to You Automatically Sign up to receive the latest news and ratings for FONR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FONR vs. The Competition Export to ExcelMetricFonarMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.90M$10.49B$5.54B$8.87BDividend YieldN/A2.09%5.39%4.10%P/E Ratio12.3316.6626.2319.90Price / Sales0.9329.93413.23113.66Price / Cash5.0822.7836.1356.90Price / Book0.623.648.045.38Net Income$10.57M$233.36M$3.15B$248.50M7 Day Performance6.87%1.00%1.44%2.04%1 Month Performance6.13%3.01%3.62%4.84%1 Year Performance-4.02%-11.64%34.68%20.23% Fonar Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FONRFonar1.7646 of 5 stars$15.41-1.3%N/A-3.1%$96.90M$102.88M12.33480News CoveragePositive NewsTMCITreace Medical Concepts2.6045 of 5 stars$5.88+2.3%$10.16+72.7%-8.1%$361.62M$209.36M-6.92250Positive NewsNPCENeuroPace3.2762 of 5 stars$11.14+4.0%$15.50+39.1%+44.1%$351.27M$79.91M-13.26170High Trading VolumeOMOutset Medical1.7047 of 5 stars$19.21+0.7%$27.00+40.6%-63.6%$337.96M$113.69M-0.66520Positive NewsHigh Trading VolumeCLPTClearPoint Neuro2.3158 of 5 stars$11.94+1.2%$25.00+109.4%+113.0%$330.27M$31.39M-15.71110High Trading VolumeNNOXNano-X Imaging1.8901 of 5 stars$5.17-1.1%$9.50+83.8%-22.2%$302.18M$11.28M-5.74190ZIMVZimVie2.3757 of 5 stars$9.35+1.0%$16.33+74.7%-44.8%$257.87M$449.75M-13.171,770SNWVSanuwave HealthN/A$32.86+9.7%N/AN/A$256.24M$32.63M-7.2140Positive NewsCATXPerspective Therapeutics1.6726 of 5 stars$3.44-8.5%$12.56+265.0%-67.7%$255.34MN/A0.0070NYXHNyxoah2.8809 of 5 stars$7.48+0.1%$14.50+93.9%+7.1%$254.43M$4.89M-3.51110DRTSAlpha Tau Medical2.5643 of 5 stars$3.12+4.7%$8.00+156.4%+45.4%$252.76MN/A-6.7880Positive News Related Companies and Tools Related Companies Treace Medical Concepts Competitors NeuroPace Competitors Outset Medical Competitors ClearPoint Neuro Competitors Nano-X Imaging Competitors ZimVie Competitors Sanuwave Health Competitors Perspective Therapeutics Competitors Nyxoah Competitors Alpha Tau Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FONR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fonar Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Fonar With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FONR Stock Alerts